Landmark BioVentures (LBV), an integrated and agile hub-and-spoke company pioneering drug development through lean and efficient approaches, today announced a strategic alliance with Axis Bio, a scientific and drug development-driven nonclinical
contract research organization. This partnership marks a significant milestone in Landmark BioVentures’ mission to deliver first-in-class therapeutics by enhancing its nonclinical pharmacology capabilities in immunology and oncology.
This alliance builds on the strong foundation of a longstanding relationship between LBV and Axis Bio, united by shared values of agility, innovation, and meaningful impact. Through this partnership, Axis Bio becomes a strategic extension of LBV’s R&D Nexus, amplifying synergies and enabling dynamic cross-fertilization between the organizations. By combining their complementary expertise, the collaboration will streamline nonclinical drug development activities, particularly in pharmacology. The integrated model is designed to promote transparency, foster flexibility, and accelerate decision-making for more efficient and effective outcomes.
Zaki Sellam, co-founder and CEO of Landmark BioVentures, expressed enthusiasm stating, “This alliance reflects LBV’s strategy to foster inclusivity and agility in its R&D activities. Axis Bio’s scientific depth, combined with its ability to challenge and validate LBV nexus’ in-house data, reinforces the robustness of the drug development process. Together, the companies are breaking traditional silos to ensure that innovative therapies reach patients more efficiently.”
Dr. Jenny Worthington, co-founder and CEO at Axis Bio, shared her perspective, “This collaboration with LBV and its Nexus takes our partnership to a new level. We are proud to contribute to these promising programs, and the daily scientific exchange between our teams creates invaluable opportunities for mutual learning and innovation.”